The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women

Journal of Surgical Oncology

Volumn 87, Issue 1, 2004, Pages 19-25

  Cengiz, Ömer ^a   Bozkurt, Betül ^a,b   Ünal, Bülent ^a   Yildirim, Osman ^a   Karabeyoǧlu, Melih ^a   Eroǧlu, Abdullah ^a   Koçer, Belma ^a   Ulaş, Murat ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast cancer; Metastatic lymph nodes; Thyroid disorders; Tumor size; Vascular invasion

Indexed keywords

LIOTHYRONINE;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; THYROID DISEASE; TUMOR VOLUME; TURKEY (REPUBLIC); ULTRASOUND;

EID: 3042813292     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20071     Document Type: Article

References (43)

1. Darendeliler E: Breast cancer biology, diagnosis, staging, and treatment. In: Topuz E, editor. Ephydemiology and etiology of breast cancer. Istanbul: Istanbul Instutute of Oncology; 1997: pp 16-39.
2. Goldman MB: Thyroid diseases and breast cancer. Epidemiol Rev 1990;12:16-28.
3. Hollingsworth DR: The Merck manual internal medicine. In: Berkow R, editor. Thyroid diseases. Rahway, NJ: Merck & Co Inc.; 1992. pp 1071-1087.
4. Guernsey DL: Thyroid hormone action. Cancer J 1993;6:4-10.
5. Leuthauser SW, Guernsey DL: Thyroid hormone affects the expression of neoplastic transformation induced by DNA transfection. Cancer Lett 1987;35:321-326.
6. Zhou-Li F, Albaladejo V, Pharaboz MOJ, et al.: Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology 1992;130:1145-1152.
7. Aydiner A: Breast cancer biology, diagnosis, staging, and treatment. In: Topuz E, editor. Ephydemiology and etiology of breast cancer. Tyrosine kinase and steroid receptors of breast cancer. Istanbul: Istanbul Instutute of Oncology; 1997. pp 66-71.
8. Privalsky ML: V-erb A, nuclear hormone receptors, and oncogenesis. Biochem Biophys Acta 1992;1114:51-62.
9. Sap J, Munoz A, Damm K, et al.: The C-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986;324:635-640.
10. Vorherr H: Thyroid function in benign and malignant breast disease. Eur J Cancer Clin Oncol 1987;23:255-257.
11. Sap J, Munoz A, Schmitt J, et al.: Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature 1989;340:242-244.
12. Huang SM, Lee JC, Wu TJ, et al.: Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 2001;25(3):302-306.
13. Shushanov S, Bronstein M, Adelaide J, et al.: VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 2000;86:47-52.
14. Miralem T, Steinberg R, Price D, et al.: VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells. Oncogene 2001;20:5511-5524.
15. Karpanen T, Egeblad M, Karkkainen MJ, et al.: Vascular endothelial growth factor C promotes tumor lymphjangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-1790.
16. Pal S, Datta K, Mukhopadhyay D: Central role of p53 regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001;61(18):6952-6957.
17. Giani C, Fierabracci P, Bonacci R, et al.: Relationship between breast cancer and thyroid disease: Relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 1996;81:990-994.
18. Brinton LA, Hoffman DA, Hoover R, et al.: Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chron Dis 1984;37:877-883.
19. Kalache A, Vessey P, Mc Pherson K: Thyroid disease and breast cancer: Findings in a large case control study. Br J Surg 1982;62:434-435.
20. Hoffman DA, McCoaney WM, Brinton LA, et al.: Breast cancer in hypothroid women using thyroid supplements. JAMA 1984;251:616-619.
21. Venturi S, Donati FM, Venturi A, et al.: Role of iodine in evolution and carcinogenesis of thyroid, breast, and stomach. Adv Clin Path 2000;4:11-17.
22. Göksel H: General surgery. In: Sayek I, editor. Breast disease. Ankara: Günes Company; 1997. pp 859-870.
23. Limanova Z, Barkmanova J, Friedmanova Z: Frequent incidence of thyropathies in women with breast carcinoma. Vnitr Lek 1998;44:76-82.
24. Smyth PPA: Thyroid disease and breast cancer. Endocrinol Invest 1993;16:396-401.
25. Martinez MB, Ruan M, Fitzpatrick A: Altered response to thyroid hormones by breast and ovarian cancer cells. Anticancer Res 2000;20:4141-4146.
26. Smyth PP, Shering SG, Kilbane MT, et al.: Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab 1998;83:2711-2716.
27. Kuller LH: Management of patients at high risk for breast cancer. In: Vogel VG, editor. Epidemiology of breast cancer. Blackwell science; 1999. pp 1-18.
28. Kilbane MT, Ajjan RA, Weetman AP, et al.: Tissue iodine content and serum-mediated I125 uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 2000;85:1245-1250.
29. Shapiro S: Commentary on relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chron Dis 1984;37:885-889.
30. Moosa AR, Price Evans DA, Brewer AC: Thyroid status and breast cancer: Reappraisal of an old relationship. Ann R Coll Surg Engl 1973;53:178-188.
31. Lemaire M, Baugnet-Mahieu L: Thyroid function in women with breast cancer. Eur Cancer Clin Oncol 1986;22:301-307.
32. Yokoe T, Iino Y, Takei H, et al.: Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Anticancer Res 1996;16:2069-2072.
33. Abe R, Hirosaki A, Kimura M: Pituitary-thyroid function in patients with breast cancer. Tohoku J Exp Med 1980;132:231-236.
34. Thomas BS, Bulbrook RD, Russell MJ, et al.: Thyroid function in early breast cancer. Eur J Cancer Clin Oncol 1983;19:1213-1219.
35. Starin JJ, Bokje E, Veer P, et al.: Thyroid hormones and selenium status in breast cancer. Nutr Cancer 1997;27:48-52.
36. Takatani O, Okumoto T, Kosano H: Relationship between the levels of serum thyroid hormones or estrogen status and the risk of breast cancer genesis in Japanese women. Cancer Res 1989;49:3109-3112.
37. Rose DP, Davis TE: Plasma thyroid-stimulating hormone and thyroxine concentrations in breast cancer. Cancer 1978;41:666-669.
38. Serafini A, Sfakianakis G, Georgiou M, et al.: Breast cyst simulating metastases on iodine-131 imaging in thyroid carcinoma. J Nucl Med 1998;39:1910-1912.
39. Shering SG, Zbar AP, Moriarty M, et al.: Thyroid disorders and breast cancer. Eur J Cancer Prev 1996;5:504-506.
40. Smyth PP, Smith Df, Murray MJ, et al.: A direct relationship between thyroid enlargement and breast cancer. J Clin Endocrinol Metab 1996;81:937-941.
41. Adamopoulos DA, Vasilaros S, Kapolla N, et al.: Thyroid disease in patients with benign and malignant mastopathy. Cancer 1986;57:125-128.
42. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J Cell Biochem 2001;36:232-246.
43. Vonderhaar BK, Tang E, Lyster RR, et al.: Thyroid hormone regulation of epidermal growth factor receptor levels in mouse mammary glands. Endocrinology 1986;119:580-585.